ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The shares of ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG) were pushing higher on Wednesday before being slammed into a trading halt this afternoon at the pharmacy operator's request.

According to the release, the company requested the halt pending the release of a big announcement. Its request states:

The trading halt is requested pending an announcement relating to a potential material transaction and is required to ensure Sigma shares are not trading on a misinformed basis.

Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

What's going on with Sigma shares?

The rumour on the street is that Sigma shares have been halted today while it prepares to announce a reverse listing deal that will see pharmacy giant Chemist Warehouse listed on the Australian share market at long last.

According to the SMH, sources have told the media outlet that the two parties are close to agreeing a deal that would see Chemist Warehouse take board control and a majority ownership of Sigma.

The sources also claim that the deal could result in Sigma seeking to raise $400 million from investors to shore up its balance sheet and provide more liquidity.

Over at the AFR, it is reporting that the company will be seeking to raise $350 million to support the reverse listing of the privately owned Chemist Warehouse business.

Neither company has confirmed the reports yet. However, ASX 300 healthcare stock Sigma intends to release an announcement in relation to the "material transaction" before the market open on Friday.

So far, this news hasn't had an impact on Wesfarmers Ltd (ASX: WES) shares this afternoon. They have continued to rise despite the rumours. The conglomerate acquired Priceline-owner Australian Pharmaceutical Industries last year for almost $800 million.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has positions in and has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Starpharma: FY26 earnings reveal strong revenue growth and improved loss

Starpharma posted a sharp rise in FY26 revenue and narrowed its loss, with new funds extending its cash runway into…

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Could this ASX biotech really jump more than 500%?

This company is in the ramp up phase.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Neuren Pharmaceuticals reports lower profit but launches first dividend

The pharmaceuticals company is returning funds to shareholders with its first ever dividend.

Read more »

A scientist examining test results.
Healthcare Shares

PolyNovo FY26 earnings: Revenue jumps, profit steady

PolyNovo posted double-digit revenue growth and positive profit for FY26, as manufacturing expansion and global reach supported its medtech ambitions.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Bell Potter says this ASX biotech could nearly double in value

The US market is starting to open up for this company.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Integral Diagnostics posts profit and dividend growth in FY26

Integral Diagnostics FY26 earnings show revenue and profit growth, higher dividend, and a positive outlook for investors.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Broker Notes

This ASX small-cap healthcare stock is tipped to double in value

This company has a good base to build on.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren share price in focus after DAYBU wins EU approval for Rett syndrome

Neuren shares are on watch after DAYBU (trofinetide) won European approval, unlocking commercial milestones and revenue opportunities.

Read more »